Bone mineral density in children and adolescents with neurofibromatosis type 1.
about
The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.Optimizing biologically targeted clinical trials for neurofibromatosis.Neurofibromatosis: chronological history and current issues.Generalized metabolic bone disease in Neurofibromatosis type IStatins, bone, and neurofibromatosis type 1Tibial geometry in individuals with neurofibromatosis type 1 without anterolateral bowing of the lower leg using peripheral quantitative computed tomography.Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.Bone mineral density in children and young adults with neurofibromatosis type 1Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.Dystrophic spinal deformities in a neurofibromatosis type 1 murine model.FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation.Motor proficiency in children with neurofibromatosis type 1Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysisBone resorption in syndromes of the Ras/MAPK pathway.Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.How does the Schwann cell lineage form tumors in NF1?The musculoskeletal phenotype of the RASopathies.Massive Soft Tissue Neurofibroma (Elephantiasis Neuromatosa): Case Report and Review of Literature.Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.Does pamidronate enhance the osteogenesis in mesenchymal stem cells derived from fibrous hamartoma in congenital pseudarthrosis of the tibia?Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.Successful treatment of congenital pseudarthrosis of the tibia: still a challenge.A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age.Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years.Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.The role of motor proficiency in bone health in genetic syndromes.Constitutional bone impairment in Noonan syndrome.The generalized bone phenotype in children with neurofibromatosis 1: a sibling matched case-control study.Multiple increased osteoclast functions in individuals with neurofibromatosis type 1.Neurofibromatosis: part 2--clinical management.Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1.Early primary tooth eruption in neurofibromatosis 1 individualsIncreased dental caries in people with neurofibromatosis 1
P2860
Q27319893-48DD048C-760F-4093-8D4B-4AF3C3095B49Q30375214-2AFD2979-BABF-41BD-87D8-3BC5D032585BQ30438898-8FDC39D3-4D25-49E3-A0CF-EB57F7E7C3F6Q30449267-CDFFFB67-B7B3-47E0-995C-346F319FFFB5Q30841192-C9EFA521-6415-4758-BD33-EF57A93C2519Q33356748-2F5DC36E-5D93-4227-A628-035E17089C6AQ33396860-9B74CEC4-1A33-4E55-BEAE-48643CB0460FQ33718764-AFADB737-6C68-4402-A4B4-58E3BF539D92Q34020971-62960D28-A1C6-4CF7-9B89-24248425ABE5Q34045437-E0CF8120-45F7-4579-AF93-537EF9A7C744Q34253927-97B97ED6-B637-490E-B8B1-97B072F92AD5Q34311272-AFDAA115-19C2-4324-81EA-626E4D86DE89Q35191542-7EC705E4-19EA-4D3F-8F7C-98DA09CCF798Q35253119-126A8A04-8DFC-4A97-8DF9-DA18E373891FQ35605308-F7AD160B-9F39-4E0A-AE5E-AD78F3FF15BAQ35605316-39CF089A-CA97-425A-A18A-5457B881BA60Q35635487-2E22C5C5-F52C-4F2D-92BB-548B79253DC4Q35635492-EF8B61D6-787B-4130-A130-71C6EAF0426BQ36380904-D2FE2F8F-5151-457E-A46C-003FD78789F2Q37120518-6DA7C058-C417-40FA-A8B7-72140375B38EQ37865455-06712FCD-9531-45BF-BC58-0091F93814EEQ38360990-8DF9A971-F025-4DDC-B21C-DA121734BFE2Q38757104-DAF52375-5F19-4062-91DC-E15C51C57CB0Q41891999-3395FEE5-6206-4638-A53D-EBF9BFE7FD86Q41917599-2BB3C0B2-07A5-47C2-A763-35BEA8860331Q42918689-285D1B13-7305-41E7-81B8-612D47F7E0DDQ43411814-33AA29F5-8C31-4E28-B112-83F9B235639FQ45187619-86B3E50C-491A-4D10-8CC4-D5BEAA39DEE8Q45846222-F8D950A8-1CEF-42F3-9D3B-F64377F05D81Q46798931-3568B8A1-37DF-4FCF-82A9-D7B43BEF710CQ51891075-7D140B4A-6E88-4451-A15D-FBF7AD7E76A2Q52905410-3D01BA78-6EA7-46A9-9BA6-4965BE0970B3Q53107807-6B536847-1823-45A3-BC24-01D5FCCC4097Q53256313-F06DFAAC-D909-4A56-BE27-01903949D32BQ53464959-2FB87014-6D93-4DEB-8249-DDE079D52E08Q54574990-DD31059C-6081-409F-BD35-CCC7EA7AB521Q57386683-59EF2887-F9C7-4623-96DD-B962D12E5A89Q57386685-65BCBEE2-6B37-44F4-95B5-E95AEFFF18E0
P2860
Bone mineral density in children and adolescents with neurofibromatosis type 1.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Bone mineral density in children and adolescents with neurofibromatosis type 1.
@ast
Bone mineral density in children and adolescents with neurofibromatosis type 1.
@en
type
label
Bone mineral density in children and adolescents with neurofibromatosis type 1.
@ast
Bone mineral density in children and adolescents with neurofibromatosis type 1.
@en
prefLabel
Bone mineral density in children and adolescents with neurofibromatosis type 1.
@ast
Bone mineral density in children and adolescents with neurofibromatosis type 1.
@en
P2093
P2860
P1476
Bone mineral density in children and adolescents with neurofibromatosis type 1.
@en
P2093
Bukhosi Dube
David A Stevenson
David H Viskochil
Hillarie Slater
John C Carey
Laurie J Moyer-Mileur
Mary Murray
Xiaoming Sheng
P2860
P356
10.1016/J.JPEDS.2006.10.048
P407
P577
2007-01-01T00:00:00Z